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Abstract—The reference standard IUR-1601 ((S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-1-(2-fluoroethyl)-5-oxopyrrolidine-2-
carboxamide) was synthesized from tert-butyl (S)-5-oxopyrrolidine-2-carboxylate, fluoroethylbromide, and 2-chloro-3-
(trifluoromethyl)benzylamine with overall chemical yield 12% in three steps. The target tracer [18F]IUR-1601 ((S)-N-(2-chloro-3-
(trifluoromethyl)benzyl)-1-(2-[18F]fluoroethyl)-5-oxopyrrolidine-2-carboxamide) was synthesized from desmethyl-GSK1482160 with 2-
[18F]fluoroethyl tosylate, prepared from 1,2-ethylene glycol-bis-tosylate and K[18F]F/Kryptofix2.2.2, in two steps and isolated by HPLC 
combined with SPE in 1-3% decay corrected radiochemical yield. The radiochemical purity was >99%, and the molar activity at end of 
bombardment (EOB) was 74-370 GBq/µmol. The potency of IUR-1601 in comparison with GSK1482160 was determined by a 
radioligand competitive binding assay using [11C]GSK1482160, and the binding affinity Ki values for IUR-1601 and GSK1482160 are 
4.31 and 5.14 nM, respectively.  
Keywords: [18F]IUR-1601 ((S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-1-(2-[18F]fluoroethyl)-5-oxopyrrolidine-2-carboxamide); 
Purinergic P2X7 receptor (P2X7R); Radiosynthesis; Competitive binding assay; Positron emission tomography 
(PET). 
The purinergic receptor P2X ligand-gated ion channel 
type 7 (P2X7R) is an adenosine triphosphate (ATP)-
gated ion-channel, and the overexpression of P2X7R is 
closely associated with neuroinflammation, which plays 
an important role in various neurodegenerative diseases 
such as Alzheimer’s disease (AD) and Parkinson’s 
disease (PD).1,2 P2X7R has become a novel molecular 
imaging target for neuroinflammation via biomedical 
imaging technique positron emission tomography 
(PET).3 Recently several radioligands targeting P2X7R 
have been developed and evaluated in animals, and the 
representative radioligands are shown in Figure 1.4-10 
However, preclinical evaluation indicated some of these 
P2X7R radioligands have significant drawbacks like 
short half-life, limited blood-brain barrier (BBB) 
penetration and/or little brain uptake. Thus an ideal 
P2X7R radioligand that can be used in the clinical 
setting to study P2X7R expression levels in 
neurodegenerative disorders remains to be discovered. 
In our previous work, we have developed and 
characterized [11C]GSK1482160 as a P2X7R 
radioligand for neuroinflammation,7,8 and clinical 
evaluation of [11C]GSK1482160 in normal human 
subjects are currently underway. The half-life (t1/2) of 
radionuclide carbon-11, 20.4 min, limits the imaging 
protocol to a maximum of about 90 min post-injection 
of a carbon-11 radiopharmaceutical, after that 
insufficient counts are available for meaningful 
measurements. If imaging were extended past 90 min, 
more complete information could be obtained regarding 
the concentration and localization of the P2X7R levels 
in the tissue. Therefore, it is attractive for us to develop 
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analogs of [11C]GSK1482160 which can be labeled with 
the radionuclide fluorine-18 (t1/2, 109.7 min). A 
fluorine-18 ligand would be ideal for widespread use, 
which permits imaging of up to 5 h post-injection, and 
will result in a better match between the 
pharmacokinetics of binding and the physical decay of 
the label. To this end a series of [18F]fluoroalkyl analogs 
of GSK1482160 will be considered as new potential 
P2X7R radioligands. In this ongoing study, we report 
here the synthesis and preliminary biological evaluation 
of a new P2X7R radioligand [18F]IUR-1601 ((S)-N-(2-
chloro-3-(trifluoromethyl)benzyl)-1-(2-
[18F]fluoroethyl)-5-oxopyrrolidine-2-carboxamide, 
[18F]3a) (Figure 1).   
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Figure 1. Radioligands for imaging of P2X7R.  
 
Our synthetic strategy was first to conduct one-step 
radiosynthesis of [18F]IUR-1601. The reference 
standard IUR-1601 ((S)-N-(2-chloro-3-
(trifluoromethyl)benzyl)-1-(2-fluoroethyl)-5-
oxopyrrolidine-2-carboxamide, 3a) and its 
corresponding precursor Cl-IUR-1601 ((S)-N-(2-chloro-
3-(trifluoromethyl)benzyl)-1-(2-chloroethyl)-5-
oxopyrrolidine-2-carboxamide, 3b) were synthesized as 
outlined in Scheme 1, according to the published 
methods.7 tert-Butyl (S)-5-oxopyrrolidine-2-carboxylate 
was reacted with 1-bromo-2-fluoroethane (or 1-bromo-
2-chloroethane) and NaH in N,N-dimethylformamide 
(DMF) to convert into amide N-alkylated product 1a (or 
1b) in 42% and 38% yield, respectively. Subsequently, 
compound 1a (or 1b) was treated with trifluoroacetic 
acid (TFA) to give acid 2a (or 2b). Without further 
purification, compound 2a (or 2b) was undergone a 
coupling reaction with 2-chloro-3-
(trifluoromethyl)benzylamine using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride 
(EDAC) or 2-ethoxy-1-ethoxycarbonyl-1,2-
dihydroquinoline (EEDQ) as catalyst, affording IUR-
1601 (or Cl-IUR-1601) in about 28% and 27% yield, 
respectively.  
 
Another precursor TsO-IUR-1601 ((S)-2-(2-((2-chloro-
3-(trifluoromethyl)benzyl)carbamoyl)-5-oxopyrrolidin-
1-yl)ethyl 4-methylbenzenesulfonate) was obtained via 
a customer synthesis service. 
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Scheme 1. Synthesis of IUR-1601 (3a) and its precursor Cl-IUR-1601 
(3b). Reaction conditions and regents: (i) BrCH2CH2X, NaH, DMF; 42% 
and 38%. (ii) TFA, CH2Cl2. (iii) EDAC, HOBt, CH2Cl2, 28% and 27%.  
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Scheme 2. One-step radiosynthesis of [18F]IUR-1601 failed. 
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Scheme 3. Model fluorination reaction at 60 ºC. 
 
One-step radiosynthesis of [18F]IUR-1601 was 
performed as indicated in Scheme 2 via a published 
method using K[18F]F/Kryptofix2.2.2 and dimethyl 
sulfoxide (DMSO) as solvent at 140 ºC for 
[18F]fallypride production.11 Both Cl-IUR-1601 and 
TsO-IUR-1601 precursors failed to produce the 
radiolabeled product [18F]IUR-1601. At the beginning, 
we suspected the reaction temperature was too high, 
then we conducted a model fluorination reaction 
without radioactivity at 60 ºC, which was monitored by 
analytical reverse-phase (RP) high performance liquid 
chromatography (HPLC). No IUR-1601 was detected, 
instead a compound (S)-N-(2-chloro-3-
(trifluoromethyl)benzyl)-5-oxo-1-vinylpyrrolidine-2-
carboxamide (vinyl-IUR-1601) was formed and 
detected by analytical RP HPLC, and confirmed by 
liquid chromatography-mass spectra (LC-MS), MS 
 
(ESI): [M+H]+ 347. The result was summarized in 
Scheme 3.    
 
A few other model reactions were carried out as shown 
in Scheme 4 and Scheme 5. The results suggested that 
TsO-IUR-1601 and Cl-IUR-1601 precursors are 
unstable, and they would easily convert to vinyl-IUR-
1601 via elimination reaction at room temperature (RT); 
IUR-1601 is also unstable under strong base and high 
temperature conditions, and it would partially form 
vinyl-IUR-1601 via elimination reaction as well; and 
thus we concluded it is impossible to use one-step 
radiosynthesis starting from either tosyl ethyl- or chloro 
ethyl- precursor to prepare [18F]IUR-1601. 
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Scheme 4. Model fluorination reaction at RT. 
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Scheme 5. Temperature and base effect on the stability of IUR-1601. The 
base for test included solid or liquid (1, 2, and 4 M) NaOH and KOH. 
 
Therefore, we turned our effort to two-step 
radiosynthesis of [18F]IUR-1601 using desmethyl-
GSK1482160 precursor and radiolabeled precursor 2-
[18F]fluoroethyl tosylate (2-[18F]FCH2CH2OTS)12 
prepared from 1,2-ethylene glycol-bis-tosylate 
(TsOCH2CH2OTs) and K[18F]F/Kryptofix2.2.2. Prior to 
the radiosynthesis, several model reactions in small 
scale (0.5-1.0 mg) without radioactivity were performed 
to investigate the solid base and reaction temperature 
effect on the fluoroethylation of cyclic amide of the 
desmethyl-GSK1482160 precursor, as indicated in 
Scheme 6. All reactions were monitored by analytical 
RP HPLC. Based on the results we obtained, we 
believed that the cyclic amide is more easily 
deprotonated and alkylated than side chain amide; 
amide alkylation is a tough reaction and requires strong 
base and high reaction temperature conditions; and 
amide fluoroethylation reaction was quickly followed 
by an elimination reaction to form vinyl-IUR-1601 
under strong reaction conditions. Further optimization 
of the reaction conditions provided the best method for 
two-step radiosynthesis of [18F]IUR-1601.   
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Scheme 6. Temperature and base effect on the fluoroethylation of cyclic 
amide of the desmethyl-GSK1482160. 
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Scheme 7. Two-step radiosynthesis of [18F]IUR-1601. 
 
Two-step radiosynthesis of [18F]IUR-1601 is indicated 
in Scheme 7. TsOCH2CH2OTs was labeled with 
K[18F]F/Kryptofix2.2.2 to form a radiolabeled precursor 
2-[18F]FCH2CH2OTs, which was simply purified by a 
C18 Plus Sep-Pak cartridge. Then 2-[18F]FCH2CH2OTs 
was reacted with desmethyl-GSK1482160 at 100-110 
ºC under basic condition (2 M KOH) for 20 min to give 
the target tracer [18F]IUR-1601. This is a two-step two-
 
pot radiosynthesis. [18F]IUR-1601 was isolated by the 
semi-preparative RP HPLC (C18 column) combined 
with solid-phase extraction (SPE) using a C18 Plus Sep-
Pak cartridge. The radiosynthesis was performed in a 
self-designed automated multi-purpose [18F]-
radiosynthesis module.13 This radiosynthesis module 
facilitated the overall design of the reaction, purification 
and reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. Each step 
reaction used a V-vial. The first step used SPE (C18 
Sep-Pak) for purification, and the second step used a 
semi-preparative C18 HPLC column for purification. 
C18 Sep-Pak trap/release was used for reformulation. 
As we previously indicated, [18F]fluoroethylation of 
amide requires high reaction temperature and strong 
base; in addition, the labeled product [18F]IUR-1601 is 
unstable under the strong reaction conditions, 
converting to vinyl-IUR-1601 by elimination reaction. 
The two-step radiosynthesis was a somewhat “hit-and-
run” radiosynthesis, which resulted in very low 
radiochemical yield. The overall radiochemical yield for 
two-step radiosynthesis of [18F]IUR-1601 was 1-3% 
decay corrected to end of bombardment (EOB) based on 
H[18F]F. The overall synthesis time was ~2 h from 
EOB. The molar activity was 74-370 GBq/µmol at 
EOB, determined by a “spike” method using analytical 
HPLC at end of synthesis (EOS). The general methods 
to increase the molar activity have been described in our 
previous works,14-16 which include rinsing the H[18F]F 
delivery line with H2[18O]O prior to the H[18F]F 
production, eliminating QMA Sep-Pak cartridge to 
trap/release the H[18F]F, and using optimized beam 
current and beam time to produce the H[18F]F. To 
facilitate the potential application of [18F]IUR-1601 in 
animals, it is necessary to improve its radiochemical 
yield. However, the chemistry nature of [18F]IUR-1601 
radiosynthesis (two-step “hit-and-run”) does not provide 
much room for the improvement. Thus, the further 
radiosynthesis optimization of [18F]IUR-1601 will focus 
on the hardware and software modification of our 
existing home-built [18F]-radiosynthesis module, such 
as enlarging the volume of reaction V-vial and revising 
the computer-controlled synthesis sequences, to 
minimize radioactivity loss.               
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.14-16 The chemical 
purity of the precursor and reference standard was 
>95% determined by RP HPLC through UV flow 
detector. The radiochemical purity of the target tracer 
was >99% determined by radio-HPLC through γ-ray 
(PIN diode) flow detector. 
 
The analytical RP HPLC system used to monitor all 
organic synthetic and radiosynthetic reactions included 
a Prodigy (Phenomenex) 5 µm C-18 column, 4.6 × 250 
mm, a gradient mobile phase (40-80%) CH3CN/3 mM 
HCOONH4, flow rate 1.8 mL/min; UV (270 nm) and γ-
ray (PIN diode) flow detectors. Table 1 lists the 
retention time (tR) data determined by this HPLC 
system for the compounds involved in the synthetic 
reactions, and their corresponding LogP and cLogP 
values calculated from ChemDraw Professional 15.1. 
 
Table 1. tR, LogP and cLogP of IUR-1601 and its 
analogs, TsOCH2CH2OTs and FCH2CH2OTs. 
Compound LogP cLogP tR (min) 
GSK1482160 1.88 2.26 N/D* 
Desmethyl-
GSK1482160 
1.64 1.59 3.46 
IUR-1601 2.07 2.51 4.47 
TsO-IUR-1601 3.58 3.97 6.48 
Cl-IUR-1601 2.59 2.63 5.08 
Vinyl-IUR-1601 2.46 2.82 4.15 
TsOCH2CH2OTs 3.64 2.91 7.32 
FCH2CH2OTs 2.13 1.57 5.88 
*N/D, Not determined. 
 
GSK1482160, desmethyl-GSK1482160 and 
[11C]GSK1482160 were synthesized in our previous 
work.7 
 
We follow the general approach to develop a fluorine-
18 radioligand. We synthesize IUR-1601 first, then we 
measure its in vitro biological activity (Ki or IC50). If the 
in vitro data is encouraging, then the radiosynthesis of 
[18F]IUR-1601 will be launched. 
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Figure 2. The result of the competitive binding assay of IUR-1601 in 
comparison with GSK1482160. 
 
The preliminary biological evaluation of IUR-1601 in 
comparison with the known P2X7R ligand 
GSK1482160 was performed by a radioligand 
competitive binding assay using [11C]GSK1482160 
following the literature method.8,17-19 The results are 
shown in Figure 2. [11C]GSK1482160 was used as the 
radioligand, GSK1482160 and buffer were used as a 
positive control and a negative control, respectively. All 
data were analyzed by GraphPad Prism 7 software using 
a curve fitting equation to fit the Ki. The binding affinity 
 
Ki values for IUR-1601 and GSK1482160 are 4.31 ± 
0.92 nM and 5.14 ± 0.85 nM (n =3), respectively. The 
IC50 values for IUR-1601 and GSK1482160 are 7.86 
nM and 7.17 nM, respectively, obtained via 
GraphPad nonlinear fit of data using one site 
completion binding analysis.    
 
The experimental details and characterization data for 
compounds 1-3 and for the tracer [11C]3a, as well as 
radioligand competitive binding assay are given.20  
 
In summary, synthetic routes with reasonable to high 
yields have been developed to produce the reference 
standard IUR-1601 and its corresponding precursors for 
labeling. One-step and two-step radiosyntheses of 
[18F]IUR-1601 have been studied. Many model 
reactions were designed to investigate the reasons that 
caused one-step synthesis of [18F]IUR-1601 to fail and 
two-step synthesis of [18F]IUR-1601 with very low 
radiochemical yield. A new P2X7R radioligand 
[18F]IUR-1601 has been successfully radiosynthesized. 
The preliminary biological evaluation results suggest 
[18F]IUR-1601 retains the P2X7R affinity of 
[11C]GSK1482160.    
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1997;24:723-731.    20. (a). General: All commercial reagents and solvents 
were purchased from Sigma-Aldrich and Fisher 
Scientific, and used without further purification. 
Melting points were determined on a MEL-TEMP II 
capillary tube apparatus and were uncorrected. 1H and 
13C NMR spectra were recorded on a Bruker Avance 
II 500 MHz NMR Fourier transform spectrometer at 
500 and 125 MHz, respectively. Chemical shifts (δ) 
are reported in parts per million (ppm) relative to an 
internal standard tetramethylsilane (TMS, δ 0.0) (1H 
NMR) and to the solvent signal (13C NMR), and 
coupling constants (J) are reported in hertz (Hz). LC-
MS analysis was performed on an Agilent system, 
consisting of an 1100 series HPLC connected to a 
diode array detector and a 1946D mass spectrometer 
configured for positive-ion/negative-ion electrospray 
ionization. The high resolution mass spectra (HRMS) 
were obtained using a Waters/Micromass LCT Classic 
spectrometer. Chromatographic solvent proportions 
are indicated as volume: volume ratio. Thin-layer 
chromatography (TLC) was run using Analtech silica 
gel GF uniplates (5 × 10 cm2).  Plates were visualized 
under UV light. Normal phase flash column 
chromatography was carried out on EM Science silica 
gel 60 (230-400 mesh) with a forced flow of the 
indicated solvent system in the proportions described 
below. All moisture- and air-sensitive reactions were 
performed under a positive pressure of nitrogen 
maintained by a direct line from a nitrogen source. 
C18 Plus Sep-Pak cartridges were obtained from 
Waters Corporation (Milford, MA).  Sterile Millex-FG 
0.2 µm filter units were obtained from Millipore 
Corporation (Bedford, MA). [11C]GSK1482160 is a 
routine radiotracer produced in our PET 
radiochemistry facility. TsO-IUR-1601 was obtained 
via a customer synthesis service, and 1H NMR was 
recorded in our laboratory to confirm its quality and 
identity.  1H NMR (CDCl3): δ 2.02-2.09 (m, 1H, CH), 
2.26-2.36 (m, 2H, CH2), 2.45 (s, 3H, CH3), 2.47-2.53 
(m, 1H, CH), 3.13 (ddd, J = 1.5, 9.0, 15.5 Hz, 1H, 
CH), 3.90-3.94 (m, 1H, CH), 4.09-4.12 (m, 1H, CH), 
4.16-4.20 (m, 1H, CH), 4.30-4.32 (m, 1H, CH), 4.63 
(dd, J = 2.0, 6.0 Hz, 2H, CH2Ph), 6.58 (t, J = 6.0 Hz, 
1H, CONH), 7.34-7.38 (m, 3H, Ph-H), 7.61 (d, J = 8.0 
Hz, 1H, Ph-H), 7.65 (d, J = 8.0 Hz, 1H, Ph-H), 7.71 
(dd, J = 1.5, 6.5 Hz, 2H, Ph-H).  
(b). tert-Butyl (S)-1-(2-fluoroethyl)-5-oxopyrrolidine-
2-carboxylate (1a): tert-butyl (S)-5-oxopyrrolidine-2-
carboxylate (3.74 g, 20 mmol was dissolved in DMF 
(30 mL) and cooled to 0 °C. Sodium hydride (1.12 g 
of 60% suspension in mineral oil, 28 mmol) was 
added to reaction mixture and stirred for 1 h. Then 1-
bromo-2-fluoroethane (4.57 g, 36 mmol) was added 
slowly and reaction mixture was allowed to warm to 
RT and stirred for overnight. The solvent was 
evaporated in vacuo, and water was added, 
subsequently the aqueous layer was extracted with 
EtOAc (100 mL × 3), and dried over MgSO4. The 
combined organic layer was concentrated, and the 
residue was purified by column chromatography on 
silica gel with eluent (1:99 MeOH/CH2Cl2) to yield 
colorless oily product 1a (1.94 g, 42%), Rf = 0.68 
(1:15 MeOH/CH2Cl2). 1H NMR (CDCl3): δ 1.48 (s, 
9H, 3 × CH3), 2.02-2.07 (m, 1H, CH), 2.32-2.39 (m, 
2H, CH2), 2.43-2.49 (m, 1H, CH), 3.30-3.44 (m, 1H, 
CH), 3.81-3.91 (m, 1H, CH), 4.20 (dd, J = 2.5, 8.5 Hz, 
1H, CH), 4.49-4.51 (m, 1H, CH), 4.58-4.60 (m, 1H, 
CH). MS (ESI): 232 ([M+H]+, 100%). 
(c). tert-Butyl (S)-1-(2-chloroethyl)-5-oxopyrrolidine-
2-carboxylate (1b): Compound 1b was prepared using 
the same procedure as described for the synthesis of 
1a by substituting 1-bromo-2-chloroethane for 1-
bromo-2-fluoroethane. Colorless oil, yield 38%, Rf = 
0.66 (1:15 MeOH/CH2Cl2). 1H NMR (CDCl3): δ 1.47 
(s, 9H, 3 × CH3), 2.05-2.09 (m, 1H, CH), 2.33-2.40 
(m, 2H, CH2), 2.42-2.48 (m, 1H, CH), 3.28-3.33 (m, 
1H, CH), 3.59-3.63 (m, 1H, CH), 3.69-3.74 (m, 1H, 
CH), 3.96 (td, J = 5.5, 8.5 Hz, 1H, CH), 4.25-4.27 (m, 
1H, CH). MS (ESI): 248 ([M+H]+, 100%). 
(d). (S)-1-(2-Fluoroethyl)-5-oxopyrrolidine-2-
carboxylic acid (2a): A solution of compound 1a (578 
mg, 2.5 mmol) in dichloromethane was added into 
TFA (1.2 mL) at RT, the reaction mixture was then 
stirred for 36 h. Subsequently the reaction mixture was 
evaporated to dry under reduced pressure. Toluene 
was added to the residue, and it was in turn also 
evaporated to give yellowish oily product, which was 
used for next step without further purification. MS 
(ESI): 176 ([M+H]+, 100%); MS (ESI): 174 ([M-H]-, 
40%).  
(e). (S)-1-(2-Chloroethyl)-5-oxopyrrolidine-2-
carboxylic acid (2b): Compound 2b was prepared 
using the same procedure as described for the 
 
synthesis of 2a by substituting 1b for 1a. MS (ESI): 
192 ([M+H]+, 100%); MS (ESI): 190 ([M-H]-, 10%). 
(f). (S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-1-(2-
fluoroethyl)-5-oxopyrrolidine-2-carboxamide (IUR-
1601, 3a): Compound 2a (438 mg, 2.5 mmol) and 2-
chloro-3-(trifluoromethyl)benzylamine (419 mg, 2.0 
mmol) were mixed with EDAC (480 mg, 2.5 mmol) 
and 1-hydrobenzotrizole (HOBt, 338 mg, 2.5 mmol) 
in dry dichloromethane (60 mL). The reaction mixture 
was stirred for overnight at RT. Then the resultant 
mixture was washed with 2 N HCl (50 mL) and 
saturated aqueous NaHCO3 (40 mL). The organic 
layer was dried over Na2SO4 and concentrated. The 
residue was purified by column chromatography on 
silica gel with eluent (2:98 MeOH/CH2Cl2) to afford a 
white solid product 3a (210 mg, 28%), Rf = 0.34 (1:15 
MeOH/CH2Cl2), mp 147-149 °C. 1H NMR (CDCl3): δ 
2.03-2.09 (m, 1H, CH), 2.31-2.40 (m, 2H, CH2), 2.49-
2.57 (m, 1H, CH), 3.21-3.30 (m, 1H, CH), 3.80 (dd, J 
= 15.5, 36.0 Hz, 1H, CH), 4.22 (dd, J = 4.0, 8.0 Hz, 
1H, CH), 4.45-4.58 (m, 2H, CH2), 4.61 (d, J = 6.0 Hz, 
2H, CH2Ph), 6.53 (br s, 1H, CONH), 7.37 (t, J = 8.0 
Hz, 1H, Ph-H), 7.59 (d, J = 8.0 Hz, 1H, Ph-H), 7.66 
(d, J = 8.0 Hz, 1H, Ph-H). 13C NMR (CDCl3): δ  
23.96, 29.51, 41.92, 42.67 (d, JC-F = 18.75 Hz), 62.55 
(d, JC-F = 1.25 Hz), 82.36 (d, JC-F = 166.25 Hz, CH2F), 
119.66 (q, JC-F = 271.25 Hz, CF3), 127.11, 127.31 (q, 
JC-F = 5.0 Hz), 129.05 (q, JC-F = 30.0 Hz), 131.85, 
133.92, 137.73, 171.51, 176.21. MS (ESI): 367 
([M+H]+, 100%); MS (ESI): 365 ([M-H]-, 50%). 
HRMS (ESI): calcd for C15H16N2O2ClF4 ([M+H]+) 
367.0836, found 367.0848. 
(g). (S)-N-(2-chloro-3-(trifluoromethyl)benzyl)-1-(2-
chloroethyl)-5-oxopyrrolidine-2-carboxamide (Cl-
IUR-1601, 3b): Compound 3b was prepared using the 
same procedure as described for the synthesis of 3a by 
substituting 2b for 2a. White solid, yield 27%, Rf = 
0.30 (1:15 MeOH/CH2Cl2), mp 127-129 °C. 1H NMR 
(CDCl3): δ  2.03-2.06 (m, 1H, CH), 2.37-2.41 (m, 2H, 
CH2), 2.48-2.52 (m, 1H, CH), 3.7-3.23 (m, 1H, CH), 
3.58-3.63 (m, 1H, CH), 3.66-3.71 (m, 1H, CH), 3.94 
(td, J = 5.0, 14.5 Hz, 1H, CH), 4.29 (dd, J = 3.5, 
8.5Hz, 1H, CH), 4.62 (d, 2H, CH2Ph), 6.44 (brs, 1H, 
CONH), 7.38 (t, J = 8.0 Hz, 1H, Ph-H), 7.60 (d, J = 
8.0 Hz, 1H, Ph-H), 7.67 (dd, J = 1.0 , 8.0 Hz, 1H, Ph-
H). MS (ESI): 383 ([M+H]+, 100%); MS (ESI): 381 
([M-H]-, 100%). 
(h). (S)-N-(2-Chloro-3-(trifluoromethyl)benzyl)-1-(2-
[18F]fluoroethyl)-5-oxopyrrolidine-2-carboxamide 
([18F]IUR-1601, [18F]3a): No-carrier-added (NCA) 
aqueous H[18F]F was produced by 18O(p,n)18F nuclear 
reaction using a Siemens Eclipse RDS-111 cyclotron 
by irradiation of H218O (2.5 mL). H[18F]F (~37 GBq) 
in [18O]water plus 0.1 mL K2CO3 solution (1.7 mg) 
and Kryptofix 2.2.2 (10 mg) in 1.0 mL CH3CN with 
additional 1 mL CH3CN were placed in the 
fluorination reaction vial (5-mL V-vial) and repeated 
azeotropic distillation (17 min) was performed at 110 
°C to remove water and to form the anhydrous 
K[18F]F-Kryptofix 2.2.2 complex. TsOCH2CH2OTs 
(14.8 mg) dissolved in CH3CN (1.0 mL) was 
introduced to the reaction vessel and heated at 100-
110 °C for 20 min to affect radiofluorination.  After 
cooling to 80 °C, the reaction mixture 2-
[18F]FCH2CH2OTs was diluted with 3.0 mL H2O, 
passed through a C18 Plus Sep-Pak cartridge, washed 
with H2O (2 mL ×3), eluted with CH3CN (2 mL × 2), 
transferred to a 10-mL V-vial, and repeated azeotropic 
distillation (17 min) was performed at 110 °C to 
remove water and to form the anhydrous 2-
[18F]FCH2CH2OTs. The precursor desmethyl-
GSK1482160 (6 mg) and 2 M KOH (10 µL) in 
CH3CN (1.0 mL) was introduced to the reaction 
vessel. The mixture was heated to 100-110 °C for 20 
min, cooled to 80 °C, and then quenched with H2O 
(2.0 mL). The mixture was injected onto the semi-
preparative HPLC column with 3 mL injection loop 
for purification, using a YMC-Pack ODS-A, S-5 µm, 
12 nm, 10×250 mm C18 (reverse phase) column; 40% 
CH3CN:60% 3 mM HCOONH4 mobile phase; 5.0 
mL/min flow rate; UV (270 nm) and γ-ray (PIN diode) 
flow detectors. The product fraction was collected in a 
recovery vial containing 30 mL water. The diluted 
tracer solution was then passed through a C-18 Plus 
Sep-Pak cartridge, and washed with water (5 mL × 5).  
The cartridge was eluted with EtOH (1 mL × 2) to 
release [18F]IUR-1601, followed by saline (10 mL). 
The eluted product was then sterile-filtered through a 
Millex-FG 0.2 µm membrane into a sterile vial. Total 
radioactivity was assayed and total volume was noted 
for tracer dose dispensing. Retention times in the 
semi-preparative HPLC system were: tR desmethyl-
GSK1482160 = 8.68 min, tR vinyl-IUR-1601 = 11.35 
min, tR IUR-1601 = 13.37 min, tR [18F]IUR-1601 = 
13.45 min, tR 2-FCH2CH2OTs = 18.16 min, tR 2-[18F] 
FCH2CH2OTs = 18.29 min, and tR TsOCH2CH2OTs = 
20.09 min. Retention times in the analytical HPLC 
system were: tR IUR-1601 = 4.42 min and tR [18F]IUR-
1601 = 4.59 min. The decay corrected radiochemical 
yields of [18F]IUR-1601 were 1-3%. 
(i). Cell culture and membrane preparation: HEK293 
cells expressing human recombinant P2X7 receptor 
(hP2X7R) were obtained from B’SYS GmbH and 
cultured according to the supplier’s procedure. Cells 
were grown to 80% confluency and then rinsed with 
phosphate-buffered saline (PBS), detached with 
trypsin, and harvested. Cell pellets were obtained by 
centrifugation at 200 g for 5 min at 4 °C. Collected 
cell pellets were frozen at −80 °C until membrane 
preparation. For the membrane preparation, pellets 
from 10 T225 flasks were homogenized in 50 mM 
Tris-HCl, 5 mM ethylenediaminetetraacetic acid 
(EDTA), and 140 mM NaCl at pH 7.4 and 4 °C. The 
homogenate was then centrifuged at 48,000 g for 20 
min at 4 °C, gently rinsed with deionized water, and 
then resuspended in 50 mM Tris-HCl at pH 7.4 and 4 
°C. This homogenate was then centrifuged as before, 
 
with the resulting pellet being homogenized in 50 mM 
Tris-HCl at pH 7.4. Total protein concentration was 
determined via the Bradford protein assay (Bio-Rad). 
Aliquots were stored in cryovials at −80 °C until the 
day of assay. 
(j). [11C]GSK1482160 standards: For each 
experiment, the highest concentration of radioactivity 
used was diluted twice in assay buffer, followed by 
eleven 2-fold dilutions. Twenty microliters of each 
dilution were then spotted onto a GF/B UniFilter-96 
plate (Perkin-Elmer) and allowed to air-dry until the 
end of the experiment. An additional 20 µL of each 
dilution were added to a scintillation vial containing 7 
mL of Optiphase Hisafe 3 (Perkin-Elmer) and counted 
on an LS6000 scintillation counter (Beckman). 
Aliquots of the working concentrations of 
radioactivity used on each day were counted in the 
same manner. 
(k). Radioligand competitive binding assay: For 
competitive binding assays, cell membrane 
preparation (0.054 mg of protein/mL of assay 
medium) was incubated with 11 compound 
concentrations over a six log unit range, with 5 
nM [11C]GSK1482160 in assay buffer (50 mM Tris-
HCl, pH 7.4, 0.1% bovine serum albumen (BSA)) .  
Triplicate determinations were done at each 
concentration of test compound. GSK1482160 was 
used to determine non-specific binding. Assays were 
incubated at 22 °C for 30 min.  For termination of the 
binding reaction, the samples were filtered onto GF/B 
UniFilter plates that had been presoaked in 0.5% 
polyethyleneimine for 30 min using a UniFilter-96 cell 
harvester. The plates were washed 5 times with ice-
cold saline, dried under a vacuum, and exposed to a 
TR2025 phosphor screen for 20–60 min. Phosphor 
screens were then read on a Typhoon FLA-7000IP 
(GE Healthcare) along with [11C]-calibration 
standards. CPMs (counts per minute) were determined 
by calibrating the image to the CPMs in the calibration 
standards via MCID analysis Software.  Data was 
analyzed with Prism 7 (GraphPad Software Inc.) to 
determine Ki values.  
 
